# Hemochromatosis

Evaluate suspected hemochromatosis with transferrin saturation and ferritin, confirm appropriate HFE genotypes, distinguish secondary hyperferritinemia, stage hepatic risk, and use phlebotomy to deplete demonstrable iron overload while avoiding treatment of genotype alone.

**Clinical question:** How should physicians confirm, stage, and treat iron overload from hereditary hemochromatosis while excluding common mimics?

Updated: 2026-09-16T01:02:04.655607+00:00

## What matters in practice
- Order serum ferritin and transferrin saturation together when iron overload is suspected; persistent ferritin elevation with transferrin saturation greater than 45% should prompt HFE genotyping. [21][24]
- An isolated ferritin elevation with normal transferrin saturation rarely represents iron overload; evaluate inflammatory, hepatic, metabolic, alcohol-related, and hematologic causes before labeling hereditary hemochromatosis. [12][22][24]
- C282Y homozygosity with biochemical iron overload establishes HFE-related hemochromatosis; non-C282Y results require documentation of hepatic iron excess and exclusion of secondary causes before diagnosing non-HFE disease. [12][23]
- Use therapeutic phlebotomy for documented iron overload, checking hemoglobin before each procedure and titrating to ferritin depletion; do not phlebotomize unaffected genotype-positive individuals solely because of genotype. [2][22]
- Ferritin greater than 1,000 µg/L or evidence of liver disease warrants hepatic fibrosis assessment and consideration of biopsy or quantitative MRI for prognostic staging. [21][23]

## Start with paired iron indices, not HFE testing alone

The initial branch is true iron loading versus hyperferritinemia without iron overload.

Order serum ferritin and transferrin saturation (TSAT) together in patients with suspected iron overload, including those with unexplained liver enzyme abnormalities, arthropathy, diabetes, cardiomyopathy, hypogonadism, suggestive family history, or prior abnormal iron studies. Ferritin reflects iron stores but also rises with inflammation and liver injury; TSAT identifies increased circulating iron availability and is an early phenotypic abnormality in HFE hemochromatosis. [20][23]

Persistent ferritin elevation with TSAT greater than 45% should trigger HFE genotyping for C282Y and H63D variants. Conversely, normal ferritin—less than 300 ng/mL in men or less than 200 ng/mL in women—together with normal TSAT has a reported 97% negative predictive value for iron overload. [12][24]

Do not diagnose hereditary hemochromatosis from ferritin alone. Isolated hyperferritinemia with normal TSAT is rarely iron overload and should redirect evaluation toward alternate causes, particularly metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, inflammatory states, or hematologic disorders. NAFLD and alcohol-associated liver disease commonly produce elevated ferritin with normal TSAT, although overlap with hemochromatosis can occur. [12][22][24]
- Obtain CBC and hemoglobin before any planned phlebotomy; anemia makes routine blood removal unsafe and should prompt reassessment of the iron-overload mechanism. [7][22]
- Measure AST, ALT, alkaline phosphatase, bilirubin, and albumin at diagnosis of biochemical iron overload to identify liver involvement and establish baseline synthetic function. [23]
- For patients with documented iron overload, assess fasting glucose and hemoglobin A1c for diabetes and obtain radiographs of symptomatic or deformed joints, especially hands, hips, and knees. [23]

*Initial interpretation of ferritin and transferrin saturation in suspected hemochromatosis. [12][21][22][24]*

| Iron-study pattern | Most useful interpretation | Next action |
| --- | --- | --- |
| Ferritin persistently elevated and TSAT >45% | Pattern supports increased iron absorption and warrants evaluation for hereditary hemochromatosis. [21][24] | Order HFE C282Y/H63D genotyping. [21][24] |
| Normal TSAT and ferritin <300 ng/mL in men or <200 ng/mL in women | Iron overload is unlikely; combined normal values have 97% negative predictive value. [12] | Pursue alternate diagnoses if clinical concern persists. [12] |
| Elevated ferritin with normal TSAT | Rarely indicates iron overload; common mimics include NAFLD and alcohol-associated liver disease. [12][22] | Evaluate hepatic, metabolic, inflammatory, and hematologic causes before genetic labeling or phlebotomy. [11][22] |
| Ferritin elevated, TSAT >45%, but non-diagnostic HFE genotype | Possible non-HFE disease or secondary iron overload; genotype alone does not establish hereditary disease. [12][24] | Document hepatic iron with MRI and exclude secondary causes. [12][24] |

## Interpret HFE genotype in the context of iron loading

Genotype defines risk but does not substitute for phenotypic evidence of iron excess.

C282Y homozygosity is the predominant genotype associated with clinically symptomatic HFE hemochromatosis and confers the greatest risk of progressive biochemical iron overload. In a patient with elevated TSAT and ferritin, C282Y homozygosity is consistent with HFE-related hemochromatosis and generally does not require further genetic testing to establish the common HFE diagnosis. [5][12]

Do not equate C282Y homozygosity with inevitable end-organ disease. Phenotypic expression has been reported in approximately 70% of C282Y homozygotes, whereas expression is less than 10% with other mutations; clinical classification should therefore distinguish biochemical iron overload from iron-overload-related organ injury. [1][23]

C282Y/H63D compound heterozygosity, H63D homozygosity, other HFE combinations, or absent common HFE variants do not independently prove hereditary hemochromatosis. When TSAT and ferritin remain abnormal in these settings, quantify hepatic iron—usually with MRI—and exclude secondary iron loading before making a presumptive diagnosis of non-HFE hemochromatosis. [12][24]

Consider non-HFE hemochromatosis particularly with young presentation and biochemical plus clinical evidence of iron overload. Non-HFE forms, especially HJV- or HAMP-mediated disease, have earlier onset and a greater propensity for cardiac and gonadal involvement; this phenotype should accelerate assessment for organ involvement and referral for specialized genetic evaluation after hepatic iron is documented. [12]
- Target HFE testing to patients with biochemical evidence of iron overload or a family history; it is not recommended as a population-screening test. [5]
- Screen first-degree relatives—especially siblings—of an affected patient with iron studies and genetic testing, recognizing that many genetically susceptible individuals never develop symptoms or complications. [15]
- Avoid phlebotomy in an unaffected C282Y homozygote or C282Y/H63D compound heterozygote without evidence of hemochromatosis; biochemical follow-up is appropriate, but an evidence-based interval is not established. [2]

*Genotype-directed next steps in suspected hereditary hemochromatosis. [2][5][12][15][23]*

| Finding | Diagnostic implication | Management consequence |
| --- | --- | --- |
| C282Y homozygosity with elevated ferritin and TSAT | Consistent with HFE-related hemochromatosis. [12] | Stage organ involvement and initiate iron-depletion therapy when iron overload is documented. [17][23] |
| C282Y homozygosity without iron overload | Genetic susceptibility with variable penetrance, not necessarily clinical disease. [1][23] | Follow biochemical indices; do not treat genotype alone. [2] |
| C282Y/H63D compound heterozygosity or another HFE genotype | Does not itself establish clinically significant hereditary iron overload. [2][12] | Confirm hepatic iron overload and evaluate competing causes before diagnosis or phlebotomy. [12] |
| No common HFE variant plus convincing iron overload | Consider non-HFE hemochromatosis only after secondary causes are excluded. [12][24] | Use hepatic MRI; pursue specialized evaluation for rare genetic disease when phenotype is compatible. [12] |

## Quantify liver iron and stage fibrosis when results change prognosis

Liver assessment determines whether iron depletion alone is sufficient or cirrhosis-directed care is needed.

Use quantitative hepatic MRI as the preferred noninvasive method to document and quantify hepatic iron deposition when HFE results are non-diagnostic, hyperferritinemia has an uncertain cause, or biopsy is not feasible. MRI can also assess iron in the spleen, pancreas, heart, and brain, which is useful when extrahepatic involvement is suspected. [23][24]

Assess hepatic fibrosis in every patient with confirmed iron overload using noninvasive testing or biopsy when clinical risk is substantial. Ferritin greater than 1,000 µg/L, abnormal liver tests, clinical evidence of cirrhosis, heavy alcohol exposure, viral hepatitis, or another coexisting liver disease should lower the threshold for fibrosis staging and liver biopsy when histology will clarify diagnosis or prognosis. [21][23][24]

Liver biopsy is no longer required to diagnose typical HFE hemochromatosis when iron indices and genotype are concordant, but remains useful when the diagnosis is unclear, when NAFLD, dysmetabolic iron overload syndrome, or alcohol-associated liver disease confounds interpretation, and when direct fibrosis assessment will change management. [23][24]

In HFE hemochromatosis cohorts, APRI greater than 0.44 and FIB-4 greater than 1.1 each identified biopsy-validated advanced fibrosis with 81% diagnostic accuracy. These lower thresholds are disease-contextual rather than general chronic-liver-disease cutoffs and should be integrated with ferritin, liver tests, elastography, imaging, and clinical findings rather than used in isolation. [21]
- Obtain liver elastography in patients with ferritin above 1,000 µg/L or other concern for fibrosis; combine it with biochemical fibrosis markers rather than relying on ferritin alone. [21][23]
- Evaluate patients with cirrhosis as having established chronic liver disease in addition to iron overload; phlebotomy removes iron but does not replace fibrosis staging or surveillance planning. [23]
- In patients with significant cardiac symptoms or a young, severe non-HFE phenotype, evaluate for cardiac iron involvement because juvenile forms have disproportionate cardiac morbidity. [12][23]

*When to escalate beyond iron studies in hemochromatosis. [12][21][23][24]*

| Trigger | Preferred assessment | Reason for escalation |
| --- | --- | --- |
| Ferritin >1,000 µg/L | Liver elastography and consideration of liver biopsy or quantitative MRI. [21][23] | Higher concern for advanced fibrosis and substantial hepatic iron burden. [21][23] |
| Non-diagnostic HFE genotype with abnormal iron studies | Quantitative hepatic MRI. [12][24] | Confirms hepatic iron before assigning non-HFE hemochromatosis. [12] |
| Abnormal liver tests or coexisting alcohol, viral, or metabolic liver disease | Fibrosis assessment; biopsy if diagnosis or prognosis remains uncertain. [23][24] | Separates iron-mediated disease from confounding liver pathology and stages fibrosis. [23][24] |
| Young onset with cardiac or gonadal involvement | Assess extrahepatic iron burden and pursue specialized evaluation for non-HFE disease. [12][23] | Juvenile non-HFE forms carry higher cardiac and gonadal risk. [12] |

## Use therapeutic phlebotomy for documented iron overload

Phlebotomy is first-line iron reduction when the patient can tolerate blood removal.

Initiate therapeutic phlebotomy for patients with HFE-related hemochromatosis and biochemical or clinical iron overload. Standard induction removes 300 to 500 mL of blood at 1- to 2-week intervals until ferritin is below 100 µg/L; each 400- to 500-mL removal eliminates approximately 200 to 250 mg of iron. [7][22]

Check hemoglobin before every phlebotomy and remeasure ferritin after every fourth procedure during induction. Once depleted, transition to individualized maintenance phlebotomy based on recurrent ferritin elevation; maintenance commonly requires three to four procedures annually in men and one to two annually in women, although frequency must follow serial hemoglobin and ferritin rather than a fixed calendar schedule. [7][22]

Published targets vary. One source describes ferritin below 100 µg/L for induction, while AASLD-derived targets cited in a recent trial report ferritin 50 to 100 ng/mL and TSAT below 50% in men or below 45% in women. Use a consistent local target and avoid iatrogenic anemia through preprocedure hemoglobin monitoring. [4][7][22]

Phlebotomy is not feasible in substantial anemia, some malignancy settings, or hemodynamic instability. Iron chelation is an alternative when phlebotomy is contraindicated or impossible, but available agents—deferoxamine, deferasirox, and deferiprone—carry drug toxicity and are generally reserved for selected patients rather than routine HFE hemochromatosis. [4][7]
- Do not begin serial phlebotomy solely for a nonhereditary genotype or unexplained abnormal iron study; inappropriate phlebotomy was common in a tertiary-center series of patients misdiagnosed with hereditary hemochromatosis. [11]
- Continue long-term surveillance after depletion because iron indices can rise again and treatment has distinct induction and maintenance phases. [4][22]
- For non-HFE hemochromatosis with documented iron overload, use an approach generally similar to HFE disease, while recognizing earlier onset and greater cardiac and gonadal risk in some genetic subtypes. [12]

### Phlebotomy monitoring

Use hemoglobin, hematocrit, ferritin, and iron indices to guide safety and maintenance frequency. If hemoglobin falls or symptoms of volume intolerance occur, defer further removal and reassess for anemia, competing illness, or an incorrect attribution of ferritin elevation to iron overload. [7][22]
- Before each removal: hemoglobin assessment. [22]
- During induction: ferritin after every fourth phlebotomy. [22]
- During maintenance: periodic hemoglobin, ferritin, and iron studies to determine the next procedure interval. [7]

*Therapeutic phlebotomy framework for documented hemochromatosis-associated iron overload. [4][7][22]*

| Treatment phase | Procedure and monitoring | Treatment endpoint or adjustment |
| --- | --- | --- |
| Induction | Remove 300-500 mL every 1-2 weeks; check hemoglobin before each procedure and ferritin after every fourth procedure. [22] | Continue until ferritin is <100 µg/L; an AASLD-derived target range is 50-100 ng/mL. [4][22] |
| Maintenance | Individualize interval using periodic hemoglobin, ferritin, and iron studies. [7] | Typical frequency is 3-4 phlebotomies/year in men and 1-2/year in women. [7] |
| Phlebotomy intolerance or contraindication | Avoid routine removal in significant anemia, malignancy, or hemodynamic instability. [7] | Consider selected chelation with deferoxamine, deferasirox, or deferiprone when blood removal cannot be used. [7] |

## Monitor phenotype and test relatives rather than screening the population

The durable management task is surveillance for recurrent iron loading and recognition of at-risk relatives.

After iron depletion, follow ferritin and TSAT with hemoglobin to determine maintenance phlebotomy timing. Genotype-positive individuals without iron overload should receive biochemical follow-up rather than empiric treatment, but available guidance does not establish a single evidence-based interval. [2][7]

Offer evaluation to first-degree relatives, especially siblings, of patients with hereditary hemochromatosis. Family-based testing is clinically useful because siblings may share genetic risk, whereas broad population HFE screening is not recommended because of low and variable penetrance. [5][15]

At diagnosis of clinically meaningful iron overload, document potentially affected systems with liver biochemical testing, diabetes screening, and targeted joint imaging. In patients with established organ injury, iron depletion should proceed alongside management of the organ-specific disease rather than being treated as a substitute for hepatic, cardiac, endocrine, or musculoskeletal care. [23]
- Interpret recurrent ferritin elevation with TSAT: normal TSAT should prompt reassessment for inflammatory or liver-related hyperferritinemia rather than automatic intensification of phlebotomy. [12][22]
- Reassess for liver fibrosis when ferritin rises substantially, liver tests become abnormal, or new cofactor liver disease is identified. [21][23]
- Prioritize earlier assessment for cardiac and gonadal involvement in suspected juvenile non-HFE disease. [12]

*Follow-up priorities after diagnosis or genetic identification. [2][5][7][12][15][23]*

| Clinical state | Follow-up priority | Avoid |
| --- | --- | --- |
| Iron-depleted treated patient | Use serial hemoglobin, ferritin, and iron indices to individualize maintenance phlebotomy. [7] | Using a fixed phlebotomy schedule without laboratory reassessment. [7] |
| C282Y homozygote without iron overload | Biochemical follow-up for evolving iron indices. [2] | Therapeutic phlebotomy solely because of genotype. [2] |
| First-degree relative of an affected patient | Offer iron studies and genetic testing, particularly for siblings. [15] | Assuming symptoms are required before testing. [15] |
| Suspected non-HFE disease at young age | Confirm hepatic iron and assess cardiac and gonadal involvement. [12] | Attributing severe early-onset disease to a common HFE genotype without phenotypic confirmation. [12] |

## References
1. Hemochromatosis: Practice Guidelines Update | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/hemochromatosis-practice-guidelines-update-JG201109090000005
2. EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH) | European Journal of Human Genetics — www.nature.com — https://www.nature.com/articles/ejhg2015128
3. Hereditary hemochromatosis and diabetes mellitus: implications for clinical practice | Nature Reviews Endocrinology — www.nature.com — https://www.nature.com/articles/nrendo.2009.241
4. A phase 1b randomised clinical trial evaluating BBI-001, a non-absorbed oral therapeutic for the treatment of iron overload | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-01421-4
5. Highly accurate molecular genetic testing for HFE hereditary hemochromatosis: results from 10 years of blinded proficiency surveys by the College of American Pathologists | Genetics in Medicine — www.nature.com — https://www.nature.com/articles/gim201634
6. Hemochromatosis | Annals of Internal Medicine - ACP Journals — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/ANNALS-24-03710
7. Iron Overload Cardiomyopathy: Better Understanding of an Increasing Disorder — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2010.03.083
8. The quality of hereditary haemochromatosis guidelines: A comparative analysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S2210740114002150
9. EASL clinical practice guidelines for HFE hemochromatosis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0168827810001972
10. Update on Hereditary Hemochromatosis and the HFE Gene - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0025619611648167
11. Hereditary Hemochromatosis: Missed Diagnosis or Misdiagnosis? - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002934313006207
12. Diagnosis and Management of Non-HFE Hemochromatosis | The Hematologist | American Society of Hematology — ashpublications.org — https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V22.1.202523/535040/Diagnosis-and-Management-of-Non-HFE
13. Diagnosis and Treatment of Hemochromatosis — www.gastrojournal.org — https://www.gastrojournal.org/article/S1542-3565(24)01136-4/fulltext
14. Part IV: DEVELOPING, IMPLEMENTING, AND EVALUATING POPULATION INTERVENTIONS | CDC — archive.cdc.gov — https://archive.cdc.gov/www_cdc_gov/genomics/resources/books/21stcent/chap23.htm
15. About Hereditary Hemochromatosis | Hereditary Hemochromatosis | CDC — www.cdc.gov — https://www.cdc.gov/hereditary-hemochromatosis/about/index.html
16. A population-based study of the biochemical and clinical expression ... — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(02)80116-0/fulltext
17. Diagnosis and management of hereditary hemochromatosis — ashpublications.org — https://ashpublications.org/hematology/article/2024/1/434/526218/Diagnosis-and-management-of-hereditary
18. Hemochromatosis: Diagnosis and management - Gastroenterology — www.gastrojournal.org — https://www.gastrojournal.org/article/S0016-5085(01)61194-6/fulltext
19. Predicting C282Y homozygote genotype for hemochromatosis using ... — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/25314357
20. HFE Genotype, Ferritin Levels and Transferrin Saturation in Patients with Suspected Hereditary Hemochromatosis — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8394043
21. Clinical practice guidelines on hemochromatosis: Asian Pacific ... — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10224841
22. Diagnosis and Treatment of Genetic HFE-Hemochromatosis: The Danish Aspect — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6785287
23. HFE-Related Hemochromatosis - GeneReviews® - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK1440
24. Laboratory Evaluation of Hereditary Hemochromatosis - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK594250

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.